Results 21 to 30 of about 43,637 (267)
In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
Pharmaceutical Biology, 2018 Context: Friedelin is a triterpenoid with several biological activities. However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.
Jinlan Wei +2 more
doaj +1 more source
Scientific Reports, 2021 Caco-2 cells are widely used as an in vitro intestinal epithelial cell model because they can form a monolayer and predict drug absorption with high accuracy. However, Caco-2 cells hardly express cytochrome P450 (CYP), a drug-metabolizing enzyme.
Moe Ichikawa +5 more
doaj +1 more source
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers [PDF]
British Journal of Clinical Pharmacology, 2008 AIMSTo assess the potential of known CYP3A4 inducers, with and without CYP3A4 inhibitors, to alter the pharmacokinetic profile of maraviroc.METHODSTwo separate, open, randomized, placebo‐controlled studies were conducted in healthy subjects. Study 1 was a 28‐day parallel‐group study with three treatment groups of 12 subjects each.
Samantha, Abel +4 more
openaire +2 more sources
Exposure to CYP3A4‐inducing and CYP3A4‐non‐inducing antiepileptic agents and the risk of fractures [PDF]
Pharmacoepidemiology and Drug Safety, 2011 ABSTRACTPurposeTo evaluate whether exposure to Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)‐inducing antiepileptics increases fracture risk compared to CYP3A4‐non‐inducing antiepileptics.MethodsWe performed a retrospective cohort study of initiators of antiepileptic agents using a UK medical record database (The Health Improvement ...
Hedi, Schelleman +6 more
openaire +2 more sources
Di-san junyi daxue xuebao, 2022 Objective To explore the differences of postoperative patient-controlled intravenous analgesia (PCIA) with sufentanil in the patients with different CYP3A4 and CYP3A5 genotypes after laparoscopic surgery. Methods According to CYP3A4 and CYP3A5 genotypes,
GU Li +4 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation of clopidogrel’s active metabolite and, respectively, its antiplatelet effect.
K. B. Mirzaev +4 more
doaj +1 more source
In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
Pharmaceutical Biology, 2019 Context: Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.
Ning Zhang +3 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2017 Aim. To study the anti-inflammatory effects of intensive lipid-lowering therapy and genetic predictors of its effectiveness in patients with very high cardiovascular risk.Material and methods.
M. A. Vorobyeva +5 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2018 The considered clinical case of combination of multifocal atherosclerotic vascular lesion with type 2 diabetes mellitus and liver fibrosis demonstrates a combination of polyvalent risk factors for resistance to antiplatelet therapy with clopidogrel. The
M. A. Andreyanova +5 more
doaj +1 more source
Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC–MS/MS
Pharmaceutical Biology, 2018 Context: Triptolide and amlodipine are often simultaneously used for reducing urine protein excretion after renal transplantation in China clinics. Objective: This study investigated the effects of triptolide on the pharmacokinetics of amlodipine in male
Chengyin Zhang +3 more
doaj +1 more source